Does Zepbound Cause Blood Clots? Safety Profile Explained

Zepbound (tirzepatide) is an FDA-approved medication for chronic weight management that works through a dual-action mechanism targeting GIP and GLP-1 receptors. As patients and healthcare providers evaluate this treatment option, questions naturally arise about potential cardiovascular risks, including whether Zepbound causes blood clots. Based on current clinical trial data and FDA prescribing information, there is no established causal link between Zepbound and blood clot formation. Understanding the medication's safety profile, independent risk factors for thromboembolism, and appropriate monitoring strategies helps ensure safe, effective weight management treatment.

We offer compounded medications and Zepbound®. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. References to Wegovy®, Ozempic®, Rybelsus®, Mounjaro®, or Saxenda®, or other GLP-1 brands, are informational only. Compounded and FDA-approved medications are not interchangeable.

What Is Zepbound and How Does It Work?

Zepbound (tirzepatide) is a prescription medication approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or dyslipidemia. Manufactured by Eli Lilly, Zepbound represents a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.

The medication works through a unique dual-agonist mechanism that targets two incretin hormone receptors simultaneously. By activating GIP receptors, tirzepatide enhances insulin secretion. The GLP-1 receptor activation slows gastric emptying, reduces appetite, and promotes satiety. This combined action leads to significant reductions in caloric intake and body weight. In clinical trials, Zepbound demonstrated dose-dependent weight loss, with participants losing approximately 15% (10 mg dose) to 20% (15 mg dose) of initial body weight over 72 weeks when combined with lifestyle modifications.

Zepbound is administered as a once-weekly subcutaneous injection, with doses starting at 2.5 mg and potentially increasing through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg. Treatment typically begins at the lowest dose, with gradual titration every four weeks to minimize gastrointestinal side effects. The medication is chemically identical to Mounjaro (tirzepatide), which is FDA-approved for type 2 diabetes management, but Zepbound is specifically indicated for weight management. Patients should not use Zepbound concurrently with other GLP-1 receptor agonists or Mounjaro.

Patients considering Zepbound should understand that it is intended for long-term use as part of a comprehensive weight management program that includes reduced-calorie diet and increased physical activity. The medication is not approved for cosmetic weight loss in individuals without obesity or weight-related health conditions.

Cardiovascular Effects and Safety Profile of Zepbound

Currently, there is no established causal link between Zepbound and blood clot formation based on available clinical trial data and FDA prescribing information. The medication has not been associated with increased rates of venous thromboembolism (VTE), deep vein thrombosis (DVT), or pulmonary embolism in controlled studies.

The cardiovascular safety profile of Zepbound has been evaluated in large-scale clinical trials involving thousands of participants. The SURMOUNT clinical trial program, which included SURMOUNT-1 through SURMOUNT-4, monitored cardiovascular events as secondary endpoints. These studies have not shown signals of increased cardiovascular risk to date, and some data suggest potential cardiovascular benefits, including reductions in blood pressure and improvements in lipid profiles. However, definitive cardiovascular outcomes are still being assessed. The ongoing SURMOUNT-MMO trial is specifically designed to evaluate major adverse cardiovascular events in patients with obesity and cardiovascular disease.

Common adverse effects of Zepbound are primarily gastrointestinal and include nausea (occurring in up to 29% of patients at the highest dose), diarrhea, vomiting, constipation, and abdominal pain. These effects are typically mild to moderate and decrease over time as the body adjusts to the medication. Small mean increases in heart rate may occur, though the clinical significance is uncertain. More serious but rare adverse effects include pancreatitis, gallbladder disease, acute kidney injury (usually secondary to dehydration from gastrointestinal symptoms), and hypoglycemia when used with other glucose-lowering medications.

The FDA prescribing information includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though the relevance to humans remains uncertain. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Zepbound is also contraindicated during pregnancy as weight loss offers no potential benefit and may cause fetal harm. Women of reproductive potential should use effective contraception during treatment, and backup contraception is recommended for 4 weeks after initiation and each dose increase due to potential reduced effectiveness of oral contraceptives. Healthcare providers should conduct thorough cardiovascular risk assessments before initiating treatment, particularly in patients with pre-existing cardiovascular conditions.

Risk Factors for Blood Clots While Taking Weight Loss Medications

While Zepbound itself has not been linked to increased blood clot risk, patients using weight loss medications should be aware of independent risk factors for thromboembolism that may coincide with weight management treatment. Obesity itself is a significant risk factor for venous thromboembolism, with obese individuals having approximately 2-3 times higher risk compared to those with normal weight, according to CDC data. This elevated baseline risk exists regardless of weight loss medication use.

Several patient-specific factors increase thrombotic risk during weight loss treatment. Prolonged immobility is a major concern, particularly in patients with severe obesity who may have limited mobility. Extended periods of sitting or bed rest significantly elevate VTE risk. Hormonal factors also play a role—women taking estrogen-containing contraceptives or hormone replacement therapy face increased clotting risk, and this risk may be compounded by obesity. Recent surgery, especially bariatric or orthopedic procedures, substantially increases thrombotic risk for several weeks postoperatively.

Other important risk factors include:

• Active cancer or cancer treatment (chemotherapy significantly increases clotting risk)

• History of previous blood clots (indicates higher risk for recurrence)

• Inherited thrombophilias such as Factor V Leiden or prothrombin gene mutation

• Smoking, which damages blood vessel walls and increases clotting tendency

• Pregnancy and postpartum period (6-week postpartum period carries highest risk)

• Chronic inflammatory conditions including inflammatory bowel disease and autoimmune disorders

Weight loss itself can alter various physiological parameters. The gradual weight loss typically observed with GLP-1 receptor agonists like Zepbound is generally considered safe, though rates vary by individual and dose. Patients with multiple risk factors should discuss thromboprophylaxis strategies with their healthcare provider, particularly if planning surgery or extended travel.

When to Seek Medical Attention While Using Zepbound

Patients taking Zepbound should be educated about warning signs that require immediate medical evaluation, including symptoms potentially related to blood clots and other serious adverse effects. Emergency medical attention is warranted for symptoms of venous thromboembolism, even though these are not known side effects of tirzepatide. Signs of deep vein thrombosis include sudden swelling, pain, warmth, and redness in one leg (typically the calf or thigh). Pulmonary embolism symptoms include sudden shortness of breath, chest pain that worsens with deep breathing, rapid heart rate, coughing up blood, and feeling lightheaded or fainting.

Patients should also seek urgent care for symptoms of acute pancreatitis, a known risk with GLP-1 receptor agonists. Warning signs include severe, persistent abdominal pain that may radiate to the back, nausea and vomiting that prevents keeping down food or liquids, and abdominal tenderness. Pancreatitis requires immediate discontinuation of Zepbound and hospitalization for supportive care. Similarly, symptoms suggesting gallbladder disease—including right upper abdominal pain, fever, yellowing of skin or eyes (jaundice), and clay-colored stools—require prompt evaluation, as rapid weight loss increases gallstone risk.

Severe dehydration from gastrointestinal side effects can lead to acute kidney injury and requires medical attention. Warning signs include decreased urination, dark urine, extreme thirst, dizziness upon standing, confusion, and rapid heartbeat. Patients should maintain adequate hydration, especially during the initial weeks of treatment or after dose increases.

Additional concerning symptoms include:

• Severe allergic reactions: difficulty breathing, facial swelling, severe rash, or throat tightness

• Thyroid tumor symptoms: neck mass, difficulty swallowing, persistent hoarseness, or trouble breathing

• Vision changes: For patients with diabetes, blurred vision or difficulty reading (potential diabetic retinopathy worsening)

• Persistent hypoglycemia: confusion, shakiness, sweating, or loss of consciousness (especially in patients taking insulin or sulfonylureas)

• Severe or persistent gastrointestinal symptoms lasting beyond the first few weeks

• Severe or persistent palpitations especially when associated with chest pain, dizziness, or fainting

• Mental health changes: While no causal relationship has been established between tirzepatide and suicidal thoughts, patients should report new or worsening depression or suicidal thoughts to their healthcare provider

Patients should maintain regular follow-up appointments with their healthcare provider, typically every 4-12 weeks during the first six months of treatment. These visits allow monitoring of weight loss progress, assessment of side effects, dose adjustments, and evaluation of cardiovascular risk factors. Before initiating Zepbound, patients should disclose their complete medical history, including any personal or family history of blood clots, cardiovascular disease, pancreatitis, kidney disease, or thyroid disorders. This comprehensive approach ensures safe and effective use of Zepbound for chronic weight management.

Frequently Asked Questions